Boehringer Ingelheim stops LUX-Head & Neck 2 and 4 trials with Gilotrif

26 July 2016

Boehringer Ingelheim has decided to stop the global LUX-Head & Neck 2 trial (NCT01345669) as well as its Asian companion trial, LUX-Head & Neck 4 (NCT02131155), evaluating Gilotrif (afatinib) in patients with locally advanced head and neck cancer who showed no signs of disease after chemotherapy.

Gilotrif/Giotrif is already approved for the second-line treatment of patients with advanced squamous cell carcinoma of the lung in the USA and Europe, and is approved in over 60 countries for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).

German family-owned pharma major Boehringer, a recent entrant to the oncology therapy sector, had hoped to show that the drug could help keep the cancer from returning, expanding the market for its already strong-selling drug. Annual sales of Gilotrif/Giotrif are expected to reach $688.10 million in 2020, according to GlobalData.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK